
Opus Genetics, Inc. (NASDAQ:IRD – Free Report) – Equities researchers at Brookline Capital Markets increased their FY2026 EPS estimates for Opus Genetics in a research note issued on Thursday, November 12th. Brookline Capital Markets analyst K. Raja now anticipates that the company will earn ($0.42) per share for the year, up from their previous forecast of ($0.87). The consensus estimate for Opus Genetics’ current full-year earnings is ($0.72) per share. Brookline Capital Markets also issued estimates for Opus Genetics’ FY2027 earnings at ($0.62) EPS.
A number of other brokerages also recently weighed in on IRD. Wedbush boosted their target price on Opus Genetics from $10.00 to $13.00 and gave the stock an “outperform” rating in a research note on Thursday, September 10th. BTIG Research reaffirmed a “buy” rating and set a $12.00 price target on shares of Opus Genetics in a research report on Wednesday, September 9th. Royal Bank Of Canada lifted their price target on Opus Genetics from $9.00 to $11.00 and gave the stock an “outperform” rating in a report on Wednesday, November 11th. Oppenheimer lifted their price target on Opus Genetics from $10.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Finally, TD Cowen assumed coverage on Opus Genetics in a research report on Wednesday, July 29th. They issued a “buy” rating on the stock. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Opus Genetics presently has a consensus rating of “Moderate Buy” and an average price target of $13.29.
Opus Genetics Stock Performance
NASDAQ:IRD opened at $3.92 on Tuesday. The company has a current ratio of 9.65, a quick ratio of 9.65 and a debt-to-equity ratio of 0.90. Opus Genetics has a 52 week low of $1.80 and a 52 week high of $7.07. The firm has a 50-day moving average price of $4.43 and a two-hundred day moving average price of $4.26.
Opus Genetics (NASDAQ:IRD – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.31). The company had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.55 million.
Insider Activity at Opus Genetics
In related news, CEO George Magrath sold 28,258 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $3.90, for a total transaction of $110,206.20. Following the completion of the sale, the chief executive officer owned 2,010,636 shares in the company, valued at approximately $7,841,480.40. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Benjamin Yerxa sold 33,189 shares of Opus Genetics stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $3.54, for a total transaction of $117,489.06. Following the completion of the sale, the president directly owned 670,917 shares in the company, valued at approximately $2,375,046.18. This represents a 4.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 673,805 shares of company stock worth $3,213,582. 11.70% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Opus Genetics
Large investors have recently modified their holdings of the stock. Nantahala Capital Management LLC raised its holdings in shares of Opus Genetics by 49.3% in the 3rd quarter. Nantahala Capital Management LLC now owns 4,569,528 shares of the company’s stock worth $22,117,000 after purchasing an additional 1,508,169 shares during the period. Marshall Wace LLP grew its holdings in Opus Genetics by 62.5% during the third quarter. Marshall Wace LLP now owns 3,161,606 shares of the company’s stock valued at $15,302,000 after purchasing an additional 1,215,997 shares during the period. BlackRock Inc. bought a new position in Opus Genetics during the second quarter valued at $12,809,000. Trails Edge Capital Partners LP bought a new position in Opus Genetics during the second quarter valued at $11,276,434. Finally, ADAR1 Capital Management LLC increased its position in Opus Genetics by 4,522.5% in the first quarter. ADAR1 Capital Management LLC now owns 1,849,004 shares of the company’s stock worth $8,413,000 after buying an additional 1,809,004 shares during the last quarter. Hedge funds and other institutional investors own 14.97% of the company’s stock.
About Opus Genetics
Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, rare conditions that can cause progressive vision loss. Its programs target specific genetic causes of these disorders, including mutations associated with Leber congenital amaurosis and retinitis pigmentosa. The company’s therapies are investigational and are designed to address the underlying genetic defects rather than only manage symptoms. Opus Genetics was formed through the combination of Opus Genetics and Ocuphire Pharma; the combined company took the Opus Genetics name and began trading on Nasdaq under the symbol IRD in 2024.
Recommended Stories
- Five stocks we like better than Opus Genetics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
